CDC hails Merck's Rotateq for efficacy

Merck has yet another validation of its childhood vaccine Rotateq, designed to prevent rotavirus in infants and children: The CDC says the shot has led to a dramatic drop in hospitalization and ER visits since its debut two years ago, and even seems to be preventing illness in unvaccinated children. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.